Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F3P4Z
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,106
Award facts
- Contract value 100% obligated
- $38,105.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $38,105.81 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 15, 2026, with an ultimate completion date of January 16, 2026. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, representing a specialty pharmaceutical product within the federal medical supply chain.
This delivery order is issued under AmerisourceBergen Drug Corp's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a single-award IDC valued at $999,999,999.00 through December 31, 2031. This comprehensive pharmaceutical prime vendor contract enables the delivery of a broad range of specialty medications, brand-name and generic drugs, vaccines, and medical supplies to support military healthcare programs globally, including Defense Health Agency facilities and other federal medical institutions. AmerisourceBergen's demonstrated capability to supply essential pharmaceutical commodities across multiple therapeutic domains through competitive procurement makes it a critical vendor within the federal medical supply chain.
Quick answers
Who was awarded contract SPE2DR26F3P4Z?
SPE2DR26F3P4Z was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26F3P4Z worth?
The government has obligated $38,106 on SPE2DR26F3P4Z.
Is contract SPE2DR26F3P4Z an order under another contract?
Yes. SPE2DR26F3P4Z is a delivery order under SPE2DR25D3008, an indefinite delivery contract.
Was contract SPE2DR26F3P4Z competed?
The extent of competition for SPE2DR26F3P4Z was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award